FDA Compliance Statement and Regulatory Framework
Transparency with our community and with regulators is a foundational commitment of the new Usroids. This page exists to provide a complete, honest account of our regulatory standing, the legal framework under which we operate, and the steps we have taken to ensure full compliance going forward.
We encourage every customer and every researcher to read this page in full before making a purchase.
What Happened in 2025: The Regulatory Record
In June 2025, the FDA conducted an enforcement action — a warehouse raid — against the original Us roids. This followed a period during which the previous ownership received and did not adequately respond to FDA warning letters. The original founders subsequently pleaded guilty to federal charges in December 2025.
We are not distancing ourselves from this record. We are naming it directly because we believe our customers deserve to know the full history of the brand they are trusting.
The original Us roids key violations included:
- Marketing research compounds using language implying human therapeutic use
- Selling products that crossed from research compound classification into unapproved drug territory
- Using trademarked pharmaceutical names in marketing materials
- Carrying prescription-only medications alongside research compounds without authorization
None of these practices exist under new ownership.
Our Current Legal and Regulatory Framework
Product Classification
All products offered by Amino Asylum under new ownership are classified and labeled as research compounds. We maintain strict separation between research compound descriptions and any therapeutic or human-use language across all marketing, social media, and packaging.
Labeling Standards
Our labeling complies with current FDA guidance on research compound products. Labels include:
- Accurate compound identification
- Purity information sourced from verified COA
- Clear “For Research Use Only — Not for Human Consumption” designation
- Lot number traceable to published COA
- No therapeutic claims of any kind
Ongoing Regulatory Counsel
We retain outside regulatory counsel with experience in FDA compliance for research compound suppliers. All material business decisions — including new product additions and marketing content — are reviewed for compliance before publication or sale.
Monitoring Regulatory Changes
The regulatory landscape for research compounds continues to evolve. Notable developments include the February 2026 HHS announcement that approximately 14 previously restricted peptides would be moved back to Category 1, restoring compounding access through licensed pharmacies with a prescription. We monitor these developments in real time and update our product catalog and compliance documentation accordingly.
Third-Party Testing as a Compliance Tool
Independent lab testing is not merely a marketing claim at the new Us-roids — it is a compliance mechanism. Every batch of every product is tested by an accredited third-party laboratory before it is made available for sale. Results are published on the relevant product pages with the laboratory name, date of testing, and specific purity findings.
We encourage customers to cross-reference our published COAs with any independent testing they conduct or commission.